Tag «ESMO 2017 Congress»

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2017 Congress Three Abstracts on Lenvima (Lenvatinib) to be Presented in Oral Session

TOKYO, Sept 1, 2017 – (JCN Newswire) – Eisai Co., Ltd. announced today that a series of abstracts highlighting updates regarding its in-house discovered Lenvima/Kisplyx (lenvatinib mesylate, “lenvatinib”, selective inhibitor of receptor tyrosine kinases with a novel binding mode), Halaven (eribulin mesylate, “eribulin”, halichondrin class microtubule dynamics inhibitor), and E7046 (prostaglandin E2 receptor EP4 inhibitor) …